神经退行性疾病中的二次蛋白质聚合物:几乎是规则而不是例外
Fabio Moda1, Arianna Ciullini1, Ilaria Linda Dellarole1
1Department of Neurology 5 - Neuropathology, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133 Milan, Italy.
Frontiers in bioscience (Landmark edition)
|November 2, 2023
概括
蛋白质聚合物,曾经认为是疾病特异性的,在多种神经退行性疾病中发现. 这种重叠表明了共享的机制和潜在的新治疗策略,如阿尔茨海默氏症和帕金森症.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生化学
- 病理学 病理学 病理学
背景情况:
- 蛋白质聚合物是帕金森病 (PD) 和阿尔茨海默病 (AD) 等神经退行性疾病的关键标志物.
- 传统上,像α-synuclein (α-syn),β-amyloid (Aβ) 和tau这样的特定蛋白质被认为是疾病特异性的生物标志物.
- 然而,越来越多的证据表明,这些聚合物在不同的神经疾病中同时发生.
研究的目的:
- 审查神经退行性疾病中蛋白质聚合的复杂模式.
- 要突出蛋白质聚合物的交叉疾病存在,如α-syn,Aβ,tau和TDP-43.
- 强调对理解疾病机制和开发治疗方法的影响.
主要方法:
- 文献综述和对蛋白质聚合模式的发现的综合.
- 对报告蛋白质聚合物在各种神经退行性疾病中同时出现的研究进行分析.
- 鉴定跨疾病生物标志物协会.
主要成果:
- 在AD,亨廷顿氏症,病和FTLD中发现的α-syn聚合物,超出PD和DLB.
- 在DLB和PD中检测到的Aβ聚合物.
- 在子疾病,α-synucleinopathies,甚至健康的老年人中发现了tau聚合物.
- 在AD,PSP,MSA,DLB和其他疾病中观察到的TDP-43聚合物,而不仅仅是FTLD/ALS.
结论:
- 蛋白质聚合比以前假设的更复杂和相互连接.
- 跨疾病蛋白质聚合表明共享的病原遗传途径.
- 了解这些复杂的相互作用对于开发神经退行性疾病的新型治疗策略至关重要.
关键词:
在TDP-43蛋白质病变中.阿尔法-同核蛋白病变的发生.生物标志物生物标志物神经退行症的神经退行症神经病理学神经病理学蛋白质聚合蛋白质的聚合物这种 tautopathies 是一个 tautopathies.更多相关视频
09:16Exogenous Administration of Microsomes-associated Alpha-synuclein Aggregates to Primary Neurons As a Powerful Cell Model of Fibrils Formation
Published on: June 26, 2018
7.6K
10:26Monitoring Cell-to-cell Transmission of Prion-like Protein Aggregates in Drosophila Melanogaster
Published on: March 12, 2018
8.1K
相关概念视频
03:03Amyloid Fibrils
9.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.6K
01:26Alzheimer's Disease: Overview
498
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
498
01:13The Proteasome
855
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
855
01:15Parkinson's Disease: Overview
564
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
564